Danish biotech Teitur Trophics says its experimental Parkinson’s treatment TT-P34 has successfully completed Phase 1 trials, showing both safety and early signs that it can reach the brain and central nervous system.
The company now plans to move into Phase 2 trials in 2027, supported by new fundraising efforts.
What the study tested
The Phase 1 trial included:
- 55 healthy volunteers
- 12 people with early-stage Parkinson’s disease
- Once-weekly subcutaneous injections of TT-P34
Key findings:
- The treatment was well tolerated at all doses
- No dose-limiting safety issues were reported
- The drug showed dose-dependent exposure in the brain and CNS
In simple terms, it was considered safe in early testing and was able to reach the target area in the body.
Why this matters
Parkinson’s disease treatments today mainly help with symptoms, such as movement control.
But they do not:
- Stop the disease
- Slow down neuron loss
- Reverse brain damage
TT-P34 is being developed as a disease-modifying therapy, meaning it aims to slow or change the progression of Parkinson’s itself, not just treat symptoms.
How TT-P34 works
TT-P34 is a cyclic peptide drug designed to support key cell functions that fail in Parkinson’s disease.
It targets:
- Mitochondria → the cell’s energy producers
- Lysosomes → responsible for cleaning damaged cellular material
These systems often stop working properly in neurodegenerative diseases, which contributes to neuron damage and disease progression.
Company background
Teitur Trophics was:
- Spun out of Aarhus University in 2020
- Backed by a €28 million Series A funding round in 2023
- Now preparing a Series B round to fund Phase 2 trials
The company is building its pipeline around peptide-based therapies for brain diseases.
How it fits into the wider Parkinson’s race
Other disease-modifying Parkinson’s treatments are also in development:
- Ambroxol is in Phase 3 trials targeting lysosomal function
- Roche’s prasinezumab is also in Phase 3, targeting alpha-synuclein
- BIIB122, a LRRK2 inhibitor from Biogen and Denali, recently failed in Phase 2b
This shows how competitive and uncertain the field still is, even in late-stage trials.
Reality check
Despite strong scientific interest, Parkinson’s disease modification has been extremely difficult to prove.
Many drugs that looked promising in early trials:
- Fail in later-stage testing
- Do not meet primary endpoints
- Are discontinued after Phase 2 or Phase 3
So while TT-P34 shows encouraging early results, it is still far from a proven treatment.
What happens next
- Phase 2 trials planned for 2027
- Series B funding currently being raised
- More detailed Phase 1 data will be presented at a Parkinson’s conference in Seoul on October 5
This next stage will be critical in determining whether TT-P34 can move beyond early promise into real clinical impact.